₹703.95
+0.13% today
· 30d +4.44%
as of 2026-09-04
Price · Daily Candles
“HCG grapples with volatile profits despite revenue surge, DIIs slightly increase stake.”
Healthcare Global Enterprises, with a market cap of ₹9794 Cr, saw annual revenue climb 14.51% YoY to ₹2545 Cr for FY26, yet net profit plunged 53.35% YoY to ₹23 Cr. Quarterly net profit further declined 40.32% YoY to ₹4 Cr, resulting in a TTM PE of 669.39 and an ROE of 0.53% (from `display_ratios`).
BULL CASE
+Annual revenue for FY26 increased by 14.51% to ₹2545 Cr, demonstrating consistent top-line expansion.
+Quarterly operating profit grew by 19.15% YoY to ₹138 Cr, with OPM improving by 1.29 percentage points.
+Shareholding data shows Domestic Institutional Investors (DIIs) slightly increased their stake by 0.02 percentage points QoQ to 18.91%.
+ML sales growth predictions are strong, with sales_1y_recent_2y rank at 0.727 and sales_1y_stable_7y at 0.673.
BEAR CASE
−Net profit saw a significant annual decline of 53.35% YoY to ₹23 Cr and a quarterly decline of 40.32% YoY to ₹4 Cr.
−The TTM PE ratio stands at a high 669.39, significantly above peer average, suggesting a rich valuation.
−The Return on Capital Employed (ROCE) is 8.0%, which is considerably lower than sector leaders like Apollo Hospitals (20.26%) and NH (22.72%).
−ML predictions for free cash flow (FCF_1Y) are weak, with ranks at 0.285 for recent 2y, 0.01 for rolling 4y, and 0.046 for stable 7y.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-06-30
REVENUE
₹695 Cr
+13.36% YoY
NET PROFIT
₹16 Cr
+175.25% YoY
OPM
19.0%
+0.51pp YoY
EPS
₹0.92
PE 669.39
Intrinsic value · DCF: N/A — ML model predicts severe Δ FCF compression (h1=-35.8%, h2=-36.3%, h3=-37.2% of mktcap), driving projected FCF negative by year 3 despite healthy current FCF. Treating as forecast outlier rather than reporting a misleading ₹0 valuation. Use the Strategy Fit and ML sections instead.
◇ Sector Position
HCG's TTM PE of 669.39 and ROCE of 8.0% position it significantly above the sector average PE, while lagging behind peers like APOLLOHOSP (PE 82.13, ROCE 20.26%), making it a high-valuation, lower-return outlier in the medical care facilities sector.
PEERPEROCE %
HCG669.398.0
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒
52
SCORE / 100
Overall
6-axis composite of the sections below.
Performance
POSITIVE
55
Valuation
STRETCHED
5
Growth
MUTED
49
Profitability
DECENT
68
Technicals
NEUTRAL
62
Risk
LOW
70
Key Stats
TTM PE
669.39
P/B
9.99
52W HIGH
₹804.65
OFF HIGH
-12.51%
MKT CAP
₹10510 Cr
◉ Active Signals
MACDNeutral-4.4683
RSI(14)Neutral50.5
Street Consensus
9 analysts₹774.0
mean target
Low ₹700.0Now ₹703.95High ₹920.0
⧉ Strategy Fit 🔒